Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Hologic raised its fiscal 2015 revenue forecast for the 2nd time this fiscal year as growth continued, profit gains accelerated and its 2nd-quarter net income topped Wall Street’s expectations.
The Bedford, Mass.-based company said it now expects to post adjusted earnings per share of $1.57 to $1.59, up from prior guidance of $1.54 to $1.57, and boosted its fiscal 2015 sales outlook from $2.57 billion to $2.60 billion to $2.60 billion to $2.62 billion. Read more
Stentys this week said it won a CE Mark ahead of schedule for its latest self-apposing coronary stent, a product that will be used with delivery system technology it acquired last June.
The early European regulatory O.K. enables Stentys to officially launch its Xposition S system at the EuroPCR conference May 19, the company said. Read more
Boston Scientific CEO Mike Mahoney, who’s overseen a turnaround at the medical device giant since taking over the corner office in 2012, today said the company is targeting double-digit earnings growth each year for the next 6 years.
Mahoney, speaking at the Marlborough, Mass.-based company’s investor day presentation in New York this morning, said Boston expects to post adjusted earnings per share of 88¢ to 92¢ this year, excluding foreign exchange effects. Read more